Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 97

Results For "non"

1224 News Found

Biorchestra announces US$45 million series C fundraising
News | February 23, 2022

Biorchestra announces US$45 million series C fundraising

he financing was significantly oversubscribed with high demand from both existing and new investors.


Agilent posts Q1 FY2022 revenue at US$ 1.67 billion
News | February 23, 2022

Agilent posts Q1 FY2022 revenue at US$ 1.67 billion

Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.


Mental healthcare app heyy raises pre-seed funding
Startup | February 22, 2022

Mental healthcare app heyy raises pre-seed funding

US $ 555,000 invested by Wavemaker Partners in pre-seed round


Binnopharm acquires two anti-bacterial brands from Dr. Reddy’s
Biotech | February 21, 2022

Binnopharm acquires two anti-bacterial brands from Dr. Reddy’s

Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company


VitaDAO and Molecule AG partner with Apollo Health Ventures to build the longevity biotech & Web3 ecosystem
Supply Chain | February 21, 2022

VitaDAO and Molecule AG partner with Apollo Health Ventures to build the longevity biotech & Web3 ecosystem

By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem


Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy
Drug Approval | February 20, 2022

Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy

Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear


Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
News | February 19, 2022

Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'

Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).


Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation
News | February 19, 2022

Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study


Natco Q3FY22 PAT up 27% to Rs 80 Cr
News | February 19, 2022

Natco Q3FY22 PAT up 27% to Rs 80 Cr

The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.


Abbott recalls powder formula manufactured at Sturgis, Mich., plant
News | February 19, 2022

Abbott recalls powder formula manufactured at Sturgis, Mich., plant

Recall does not include any metabolic deficiency nutrition formulas